Treatment options for recurrent glioblastoma: Pitfalls and future trends

Enrico Franceschi, Alicia Tosoni, Stefania Bartolini, Valeria Mazzocchi, Antonio Fioravanti, Alba A. Brandes

Research output: Contribution to journalArticlepeer-review


Standard treatment with temozolomide and radiotherapy for patients with newly diagnosed glioblastoma has increased the median overall survival and, more importantly, the 2-year survival rate of patients. However, as yet, no investigations have been conducted to define effective strategies against recurrence, which occurs in most patients following combined radiotherapy/temozolomide treatment. Furthermore, in recent years, new issues have emerged regarding the evaluation of disease response, and also with the identification of patterns such as pseudoprogression, frequently indistinguishable from real disease progression. New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed.

Original languageEnglish
Pages (from-to)613-619
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number5
Publication statusPublished - 2009


  • Glioblastoma
  • Radiotherapy
  • Recurrent
  • Target therapy
  • Temozolomide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Treatment options for recurrent glioblastoma: Pitfalls and future trends'. Together they form a unique fingerprint.

Cite this